These combination therapies of anti-PD-1 and anti-angiogenesis antibodies in particular may exhibit a more promising anti-HCC efficacy by both downregulating tumor angiogenesis and limiting the activity of immunosuppressive cells in the tumor microenvironment, hence promoting cytotoxic T cells to re-express their antitumor effect [181]. Here, PDCD1 is linked to hepatocellular carcinoma.